Andrew Bellizzi
Overview
Explore the profile of Andrew Bellizzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grewal U, Fei N, Chandrasekharan C, Bellizzi A, Sethi S, Gosse M
Am J Med
. 2024 Dec;
PMID: 39732152
No abstract available.
2.
Loree J, Chan D, Lim J, Stuart H, Fidelman N, Koea J, et al.
JAMA Oncol
. 2024 Oct;
10(12):1707-1720.
PMID: 39361298
Importance: Evidence-based treatment decisions for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) require individualized patient-centered decision-making that accounts for patient and cancer characteristics. Objective: To create an accessible guidance document to educate...
3.
Skopec Z, Alsawas M, Maxwell T, Pelletier D, Brown-Joel Z, Bellizzi A, et al.
J Cutan Pathol
. 2023 Oct;
51(2):163-169.
PMID: 37853944
Background: IgG4-related disease (IgG4-RD) represents a recently characterized multisystemic fibroinflammatory condition that can manifest a spectrum of skin findings (IgG4-related skin disease; IgG4-RSD). Histopathologic and immunohistochemical criteria have been proposed;...
4.
Tow D, Tran C, Borbon L, Ridder M, Li G, Kaemmer C, et al.
bioRxiv
. 2023 Apr;
PMID: 37066322
Small bowel neuroendocrine tumors (SBNETs) originate from enterochromaffin cells in the intestine which synthesize and secrete serotonin. SBNETs express high levels of tryptophan hydroxylase 1 (Tph1), a key enzyme in...
5.
Akgul M, Humble R, Osme A, Yuce S, Kocak E, Najafzadeh P, et al.
Diagn Pathol
. 2022 Nov;
17(1):87.
PMID: 36320040
Background: Clear cell adenocarcinoma of the lower urinary tract (CCACLUT) is a rare primary malignant neoplasm with heterogenous morphology. There is a paucity of data in the literature regarding its...
6.
Witt B, Zhou W, Ambaye A, Bellizzi A, Booth C, Sundling K, et al.
Arch Pathol Lab Med
. 2022 May;
147(2):143-148.
PMID: 35639575
Context.—: Most laboratories currently use patient tissues for validating immunohistochemical stains. Objective.—: To explore advantages of using cell lines with known antigenicity as a validation method. Design.—: Five American Type...
7.
Fernandez A, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al.
JAMA Oncol
. 2022 Feb;
8(4):1-4.
PMID: 35113160
Importance: Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1+ or 2+ but not 0 as read in central pathology laboratories....
8.
Ghosh T, Greipp P, Knutson D, Kloft-Nelson S, Jenkins S, Mounajjed T, et al.
Arch Pathol Lab Med
. 2021 Oct;
146(7):840-845.
PMID: 34614142
Context.—: Comprehensive genomic profiling has demonstrated that approximately 20% of pancreatic carcinomas with acinar differentiation harbor potentially targetable BRAF fusions that activate the MAPK pathway. Objectives.—: To validate the above...
9.
Borcherding N, Vishwakarma A, Voigt A, Bellizzi A, Kaplan J, Nepple K, et al.
Commun Biol
. 2021 Jan;
4(1):122.
PMID: 33504936
Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the...
10.
Ye Y, El Haija M, Morgan D, Guo D, Song Y, Frank A, et al.
Cell Rep
. 2020 Oct;
33(4):108270.
PMID: 33113371
The exact mechanisms underlying the metabolic effects of bariatric surgery remain unclear. Here, we demonstrate, using a combination of direct and indirect calorimetry, an increase in total resting metabolic rate...